MIRRORS

• Research type

  Research Study

• Full title

  Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival

• IRAS ID

  261933

• Contact name

  Christina Uwins

• Contact email

  Christina.Uwins@nhs.net

• Sponsor organisation

  Royal Surrey NHS Foundation Trust

• Clinicaltrials.gov Identifier

  NCT04402333

• Duration of Study in the UK

  1 years, 6 months, 1 days

• Research summary

  MIRRORS "Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival" is a new UK based prospective feasibility study the purpose of which is to establish the feasibility of launching a British multicentre randomised control trial of Robotic interval debulking surgery for ovarian cancer in the future. This initial feasibility study will focus on the ability to recruit patients, acceptability, quality of life, the rate at which it is possible to remove all visible tumour and the rate of conversion to open surgery. Ultimately we would like to determine whether, in selected patients, robotic surgery offers improved quality of life and recovery with equivalent overall and progression free survival.
  The study will be offered to all adult women with ovarian cancer who have had chemotherapy prior to surgery. Women will be identified through our multi-disciplinary team meeting. A Pelvic Mass >8cm and extensive disease requiring liver / upper Gastro-intestinal surgical support will exclude patients if an open surgical approach is necessary.
  Robotic surgery is unlikely to be suitable in all cases of ovarian cancer, particularly those with large pelvic masses or extensive disease around the upper part of the abdomen, however, it has the potential to provide significant recovery and quality of life benefits to a selected group of patients.
  MIRRORS – ICG “Peritoneal angiography / perfusion assessment using Indocyanine green (ICG) in patients with advanced ovarian cancers” is a ancillary study within MIRRORS. Using ICG dye, we aim to observe whether there are any changes in the blood vessel pattern associated with the tumour deposits we remove that makes them distinctive. The ICG will not be used to guide where biopsies are taken or tissue is removed. Participation in this ancillary research is not required for participation in the trial.

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  20/LO/0262

• Date of REC Opinion

  6 Mar 2020

• REC opinion

  Favourable Opinion